Sarepta settles patent litigations with REGENXBIO and UPenn for $39M

Sarepta Therapeutics, Inc.

Sarepta to pay REGENXBIO $39.0M lump sum within 10 days to settle patent disputes over AAVrh74 capsid and ELEVIDYS.
Settlement resolves infringement claims involving U.S. Patents 11,680,274 and 10,526,617; releases Sarepta and Catalent from past claims.
Parties agree to dismiss pending litigations with prejudice; no admission of liability; each bears own costs.
Company had recorded $39.0M litigation contingency charge in Q2 2026 related to anticipated settlement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.